Compare RJET & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RJET | SPRY |
|---|---|---|
| Founded | 1982 | 2015 |
| Country | United States | United States |
| Employees | 8400 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 930.0M | 823.2M |
| IPO Year | N/A | 2020 |
| Metric | RJET | SPRY |
|---|---|---|
| Price | $20.78 | $7.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 111.5K | ★ 1.7M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | N/A | $87.40 |
| Revenue Next Year | N/A | $81.64 |
| P/E Ratio | $0.21 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.37 | $6.66 |
| 52 Week High | $23.88 | $18.63 |
| Indicator | RJET | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 53.38 | 35.06 |
| Support Level | $16.65 | $6.66 |
| Resistance Level | $21.31 | $8.61 |
| Average True Range (ATR) | 1.87 | 0.52 |
| MACD | 0.21 | -0.10 |
| Stochastic Oscillator | 63.95 | 14.57 |
Republic Airways Holdings Inc is a regional airline mainly in North America. The company provides scheduled passenger service through its mainline partnerships with American Airlines, Delta Air Lines, and United Airlines. Republic offers scheduled passenger service on several daily flights to various cities in the United States, Canada, Mexico, and the Caribbean. It exclusively operates the dual-class Embraer E170/175 family of aircraft, and provides its services under the American Eagle, Delta Connection, or United Express brands. The company is organized and operates as one operating and reportable segment: regional airline services.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.